Skip to content

CeriBell, Inc. CBLL Non Us — Total Assets

Similar metrics at other companies

LSI Industries logo
LYTSNon Us — Total Assets
$0
Beta Bionics, Inc. Common Stock logo
BBNXNon Us — Total Assets
$0
PJT Partners logo
PJTNon Us — Total Assets
$96.19M+26.4%
J&J Snack Foods logo
JJSFNon Us — Total Assets
$68.2M
Granite Construction logo
GVANon-US — Total Assets
$23.5M+25.0%
PTC Therapeutics logo
PTCTNon Us — Total Assets
$373.73M+3.3%

Other financials

Income statement

See full
Revenue$26.5M+29.3%
Gross profit$23.1M+28.4%
Operating income-$20.7M-46.0%
Net income-$19.7M-54.5%
EPS (diluted)-$0.52-44.4%

Balance sheet

See full
Cash & equivalents$45.3M-70.5%
Total debt$22.1M+1.6%
Total equity$140.8M-22.2%
Total assets$178.1M-16.6%

Cash flow

See full
Operating cash flow-$19.3M-69.2%
CapEx$125.0K-15.5%
Free cash flow-$19.4M-68.1%

Valuation

See full
Market cap$748.61M+15.6%
Enterprise value$725.47M+40.7%
P/S7.9×-1.2×

Profitability

See full
Gross margin87.7%+0.5pp
Operating margin-68.3%+5.5pp
Net margin-63.5%+1.0pp
FCF margin-52%-1.4pp

Returns & leverage

See full
Return on equity-37.5%
Debt / equity0.2×0.0×
Current ratio10.4×-6.9×

Where this comes from

Reported directly by CeriBell, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Assets.

The official record: CeriBell, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about CeriBell, Inc.'s non us — total assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CeriBell, Inc.'s non us — total assets?
CeriBell, Inc. (CBLL) reported non us — total assets of $900K in Q1 2026.
What does non us — total assets mean?
This metric represents the total book value of tangible and intangible assets held by the company in geographic regions outside of its primary domestic market. It reflects the company's investment in international infrastructure, distribution networks, and regional operations required to support global commercialization of its medical technology. Monitoring this value helps investors assess the scale of the company's international footprint and the allocation of capital toward non-domestic growth opportunities.